Hollander David, Veradermics, Inc.’s Chief R&D Officer, was awarded 9,650 shares and 19,300 derivative securities on 2026-09-01. The recorded post-transaction holdings match those awards, giving investors a precise view of the Equity and derivative securities attributed to him after the transaction.

Key Highlights

  • Hollander David was awarded 19,300 derivative securities of Veradermics, Inc. on 1 September 2026.
  • His post-transaction holdings included 19,300 derivative securities.
  • The SEC transaction code assigned to the awards was A.

Hollander David, Veradermics (NYSE: MANE), Inc.’s Chief R&D Officer, was awarded 9,650 shares on 1 September 2026. His post-transaction share ownership was recorded at 9,650 shares. The transaction also includes an award of 19,300 derivative securities.

Veradermics Awards Cover Shares and Derivatives

Both categories carry the date 1 September 2026. The SEC transaction code for each award was A. Hollander David is identified as Veradermics, Inc.’s Chief R&D Officer, and the recorded holdings correspond to the respective awards.